Placebo for Navitoclax + Ruxolitinib + Navitoclax
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myelofibrosis (MF)
Conditions
Myelofibrosis (MF)
Trial Timeline
Sep 29, 2020 → Jan 29, 2025
NCT ID
NCT04472598About Placebo for Navitoclax + Ruxolitinib + Navitoclax
Placebo for Navitoclax + Ruxolitinib + Navitoclax is a phase 3 stage product being developed by AbbVie for Myelofibrosis (MF). The current trial status is completed. This product is registered under clinical trial identifier NCT04472598. Target conditions include Myelofibrosis (MF).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04472598 | Phase 3 | Completed |
Competing Products
20 competing products in Myelofibrosis (MF)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| Nusivertib + Ruxolitinib + Momelotinib | Sumitomo Pharma | Phase 1/2 | 41 |
| Ruxolitinib + Navitoclax | AbbVie | Phase 2 | 52 |
| ABBV-744 + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Mivebresib + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Navitoclax + Venetoclax | AbbVie | Pre-clinical | 23 |
| Navitoclax + Ruxolitinib + Best Available Therapy (BAT) | AbbVie | Phase 3 | 77 |
| NS-018 + Best Available Therapy | Nippon Shinyaku | Phase 2 | 52 |
| AZD1480 | AstraZeneca | Phase 1 | 33 |
| Bomedemstat | Merck | Phase 2 | 52 |
| Peginterferon alfa-2a | Merck | Phase 2 | 52 |
| Bomedemstat | Merck | Phase 1/2 | 41 |
| MBG453 + NIS793 + Spartalizumab + Decitabine | Novartis | Phase 1 | 33 |
| PIM447 + Ruxolitinib + LEE011 | Novartis | Phase 1 | 33 |
| LDE225 + INC424 | Novartis | Phase 1/2 | 41 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793 | Novartis | Phase 1/2 | 41 |
| Ruxolitinib + Ruxolitinib Placebo | Novartis | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |
| ruxolitinib | Novartis | Phase 2 | 52 |